Edition:
United States

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
8 Dec 2017
Change (% chg)

$-0.03 (-1.67%)
Prev Close
$1.80
Open
$1.81
Day's High
$1.81
Day's Low
$1.70
Volume
30,019
Avg. Vol
279,024
52-wk High
$4.25
52-wk Low
$0.63

Select another date:

Wed, Nov 29 2017

BRIEF-Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002

* CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002

BRIEF-Capricor Therapeutics reports Q3 loss per share $0.12

* Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program

BRIEF-Capricor says results from Duchenne muscular dystrophy trial to be presented at AHA late-breaking session

* Capricor announces 12-month results from HOPE-1 trial in Duchenne muscular dystrophy to be presented at AHA late-breaking session Source text for Eikon: Further company coverage:

BRIEF-Capricor Therapeutics ‍enters into common stock sales agreement

* Capricor Therapeutics - ‍entered into common stock sales agreement - sec filing

BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy

* Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy with naming of principal investigator

BRIEF-Capricor to present 6-month results from the randomized hope trial of CAP-1002

* Capricor Therapeutics to present six-month results from the randomized hope trial of CAP-1002 in duchenne muscular dystrophy in a late breaking session of the world muscle society Source text for Eikon: Further company coverage:

BRIEF-Capricor Therapeutics Q2 loss per share $0.16

* Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update

BRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option

* Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision

BRIEF-Capricor unit enters into amendment to CIRM notice of loan award

* Capricor Therapeutics Inc - ‍on June 7, unit of co entered into amendment no. 2 to CIRM notice of loan award - SEC filing​

Select another date: